Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 559 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pancreatic Surgery Clear all
Active, not recruiting Phase 1 Interventional

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT01660971
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Dasatinib, Erlotinib Hydrochloride, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery

NCT00003798
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
motexafin gadolinium, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

NCT00837876
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Sorafenib, Erlotinb
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Paducah, Kentucky • Chattanooga, Tennessee • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 19, 2026, 9:15 PM EDT
Active, not recruiting Phase 2 Interventional

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

NCT03563248
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Losartan, Nivolumab, SBRT, Surgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol

NCT02844517
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Artificial Pancreas
Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Years to 74 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 4 Interventional Results available

Glargine U300 Hospital Trial

NCT03013985
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glargine U300, Glargine U100, Glulisine Insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index

NCT03092310
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Artificial Pancreas Device
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

NCT00833859
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
GTX (gemcitabine, docetaxel and capecitabine), stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive

NCT01262040
View directory record Official record
Conditions
Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Gastrointestinal Carcinoma, Pancreatic Carcinoma, Lung Cancer, Esophageal Carcinoma
Interventions
Narrow Band Imaging (NBI)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 19, 2026, 9:15 PM EDT
Completed No phase listed Observational

DNA Microarray Study of Pancreas Cancer

NCT00680420
View directory record Official record
Conditions
Pancreas Cancer
Interventions
fine needle aspiration biopsy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

NCT00456599
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine, oxaliplatin, Radiation
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Natural Orifice Translumenal Endoscopic Surgery (NOTES) Cystgastrostomy for the Treatment of Pancreatic Pseudocysts

NCT00541593
View directory record Official record
Conditions
Pancreatic Pseudocyst
Interventions
Pancreatic Pseudocystgastrostomy
Procedure
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 19, 2026, 9:15 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers

NCT03623984
View directory record Official record
Conditions
Neuroendocrine Carcinoma of Pancreas, Carcinoid
Interventions
Gallium Dotatate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Not applicable Interventional

Prehab for Pancreatic Cancer Surgery

NCT07478185
View directory record Official record
Conditions
Pancreatic Cancer, Adult, Prehabilitation
Interventions
Multimodal Prehabilitation
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Worester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

NCT01234935
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method
Drug · Other · Genetic
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
17
States / cities
Alhambra, California • Fullerton, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 19, 2026, 9:15 PM EDT
Active, not recruiting Early Phase 1 Interventional

PHL Treatment in Pancreatic Cancer

NCT05365893
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Paricalcitol, Hydroxychloroquine, Losartan, Neoadjuvant therapy and surgery only (Control)
Combination Product · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

NCT03816358
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Active, not recruiting Phase 2 Interventional

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

NCT03073785
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, Zoledronic Acid
Drug · Other · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting Phase 2 Interventional

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

NCT05604560
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Tislelizumab, SX-682
Drug
Lead sponsor
Lei Zheng
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 9:15 PM EDT
Withdrawn Early Phase 1 Interventional

Intraductal Liposomal Bupivacaine for Chronic Pancreatitis

NCT04611958
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
ERCP with Bupivacaine infusion
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 19, 2026, 9:15 PM EDT
Terminated No phase listed Observational

Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors

NCT01455311
View directory record Official record
Conditions
Pancreatic Tumors
Interventions
EUS Guided Fine Needle Aspiration, EUS Guided EchoBrush Sampling
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 19, 2026, 9:15 PM EDT
Completed No phase listed Observational

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

NCT00369109
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pancreatic Cancer
Interventions
biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 19, 2026, 9:15 PM EDT
Recruiting No phase listed Observational

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

NCT06600906
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Hyperpolarized 13C-Pyruvate, Computed tomography (CT), Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 19, 2026, 9:15 PM EDT
Withdrawn Phase 2 Interventional

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT04130399
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX
Radiation · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 19, 2026, 9:15 PM EDT